Number 750 • July 2018

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Quinapril 5 mg Tablet (DIN 02248499) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 8, 2018**.

QUINAPRIL

5 MG TABLET

00002248499	APO-QUINAPRIL	APX	\$ 0.2321
00002290987	GD-QUINAPRIL	GMD	\$ 0.2321
00001947664	ACCUPRIL	PFI	\$ 0.9514

Alberta Blue Cross has been advised by Actavis Pharma Company and Apotex Inc. that the shortages of Act Olmesartan HCT 20 mg/12.5 mg Tablet (DIN 02443112) and Apo Olmesartan HCTZ 20 mg/12.5 mg Tablet (DIN 02453606) respectively have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 8, 2018**.

OLMESARTAN MEDOXOMIL/ HYDROCHLOROTHIAZIDE

20 MG / 12.5 MG TABLET

00002443112	ACT OLMESARTAN HCT	APH	\$ 0.6038
00002453606	APO-OLMESARTAN/HCTZ	APX	\$ 0.6038
00002319616	OLMETEC PLUS	MFC	\$ 1.1054

Alberta Blue Cross has been advised by Actavis Pharma Company and Apotex Inc. that the shortages of Act Olmesartan HCT 40 mg/12.5 mg Tablet (DIN 02443120) and Apo Olmesartan HCTZ 40 mg/12.5 mg Tablet (DIN 02453614) respectively have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 8, 2018**.

OLMESARTAN MEDOXOMIL/ HYDROCHLOROTHIAZIDE

40 MG / 12.5 MG TABLET

00002443120	ACT OLMESARTAN HCT	APH	\$ 0.6038
00002453614	APO-OLMESARTAN/HCTZ	APX	\$ 0.6038
00002319624	OLMETEC PLUS	MFC	\$ 1.1054

Alberta Blue Cross has been advised by Jamp Pharma Corporation and Pharmascience Inc. that the shortages of Jamp-Risperidone 1 mg/ml Oral Solution (DIN 02454319) and pms-Risperidone 1 mg/ml Oral Solution (DIN 02279266) respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 10, 2018**.

RISPERIDONE TARTRATE

1 MG / ML ORAL SOLUTION

00002454319	JAMP-RISPERIDONE	JPC	\$ 0.4895
00002279266	PMS-RISPERIDONE	PMS	\$ 0.4895
00002236950	RISPERDAL	JAI	\$ 1.4118

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage of Teva-Budesonide 0.5 mg/ml Inhalation Suspension (DIN 02465957) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 17, 2018**.

BUDESONIDE

0.5 MG / ML INHALATION SUSPENSION

00002465957	TEVA-BUDESONIDE	TEV	\$ 0.6839
00001978926	PULMICORT NEBUAMP	AZC	\$ 0.9023

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage of pms-Ramipril-HCTZ 10 mg/25 mg Tablet (DIN 02342170) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 17**, **2018**.

RAMIPRIL/ HYDROCHLOROTHIAZIDE

10 MG / 25 MG TABLET

00002342170	PMS-RAMIPRIL-HCTZ	PMS	\$ 0.2765
00002283182	ALTACE HCT	VCL	\$ 0.5093

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit ab.bluecross.ca/providers/pharmacy-home.php**



